Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Decreased by Associated Banc Corp

Key Points

• Associated Banc Corp has reduced its holdings in Thermo Fisher Scientific by 1.3%, selling 597 shares and now owning 45,277 shares valued at approximately $22.5 million.
• Several institutional investors have significantly increased their stakes in Thermo Fisher, with GAMMA Investing LLC expanding its holdings by over 60,000% in the first quarter.
• Thermo Fisher recently declared a quarterly dividend of $0.43 per share, with a total annualized payout of $1.72 and a yield of 0.4%.

Associated Banc Corp reduced its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,277 shares of the medical research company's stock after selling 597 shares during the period. Associated Banc Corp's holdings in Thermo Fisher Scientific were worth $22,530,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Bernard Wealth Management Corp. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $25,000. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at $30,000. IMA Advisory Services Inc. purchased a new position in Thermo Fisher Scientific during the 1st quarter valued at about $35,000. Navigoe LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new position in shares of Thermo Fisher Scientific in the first quarter valued at approximately $37,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TMO. Argus cut their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Royal Bank Of Canada dropped their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Raymond James Financial reiterated an "outperform" rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. HSBC reissued a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, UBS Group boosted their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Six research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the sale, the chief executive officer directly owned 115,174 shares of the company's stock, valued at $52,037,916.68. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 18,400 shares of company stock worth $8,345,792 over the last quarter. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of TMO traded up $6.15 during mid-day trading on Thursday, reaching $455.09. 1,490,140 shares of the company's stock were exchanged, compared to its average volume of 3,299,804. The company has a 50-day simple moving average of $425.62 and a two-hundred day simple moving average of $464.94. The company has a market cap of $171.85 billion, a price-to-earnings ratio of 26.32, a PEG ratio of 2.40 and a beta of 0.74. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the company earned $5.37 earnings per share. The business's revenue for the quarter was up 2.9% compared to the same quarter last year. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.